Jordan Milner, MD - Research

Research at a glance

Focus

Dr. Milner's research focus is graft manipulation. The utilization of graft manipulation permits decreased morbidities and improved quality of life in stem cell transplant recipients.

Active clinical trials

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Ap

Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a鈥�

Investigator: Jordan Milner
Status: Accepting Candidates
Ages: 0 Years - 25 Years
Sexes: All

(FPBCC) Retrospective CIBMTR Data Analysis

Investigator: Jordan Milner
Status: Accepting Candidates

BMT12108, Non-Myeloablative Conditioning and Bone Marrow Transplantation

Allogeneic blood or marrow transplantation (alloBMT) is a curative therapy for a variety of hematologic disorders, including sickle cell disease and thalassemia. Even when it is clear that alloBMT can give to these patients an improvement in their鈥�

Investigators: Jordan Milner, Biljana Horn
Status: Accepting Candidates
Ages: 1 Year - 70 Years
Sexes: All

My publications

9 publications

2024

Avatrombopag for severe refractory thrombocytopenia in a pediatric patient with ALL following allogeneic hematopoietic stem cell transplantation: A case report.

Leukemia research reports

鈥�

2024

Neurocognitive outcome in children with sickle cell disease after myeloimmunoablative conditioning and haploidentical hematopoietic stem cell transplantation: a non-randomized clinical trial

Frontiers in Neurology

鈥�

2024

The role of donor type and pre-transplant immunosuppression on outcomes of hematopoietic stem cell transplantation in children and young adults with severe aplastic anemia.

Pediatric transplantation

鈥�

2023

Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD

Blood

鈥�

2022

Concomitant Ruxolitinib and Ibrutinib for Graft-versus-Host Disease (GvHD): First Reported Use in Pediatric Patients

Cureus

BOB体育

Research at a glance

Focus

Active clinical trials

My publications

Filter publications

Avatrombopag for severe refractory thrombocytopenia in a pediatric patient with ALL following allogeneic hematopoietic stem cell transplantation: A case report.

Neurocognitive outcome in children with sickle cell disease after myeloimmunoablative conditioning and haploidentical hematopoietic stem cell transplantation: a non-randomized clinical trial

The role of donor type and pre-transplant immunosuppression on outcomes of hematopoietic stem cell transplantation in children and young adults with severe aplastic anemia.

Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD

Concomitant Ruxolitinib and Ibrutinib for Graft-versus-Host Disease (GvHD): First Reported Use in Pediatric Patients